VIP for Trigeminal Issues: Evidence on Repair Pathways
What's breaking down
The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.
Why VIP might help you
- Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.
How these fit together
Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- VIP → immune / autonomic
What the evidence actually shows
This is a count of what is in this ledger — not a claim about all research worldwide.
- Scientific sources catalogued (PubMed, trials, reviews): 4
- Claims tagged human evidence: 3
- Claims tagged preclinical (animal/lab): 1
- Claims tagged anecdotal: 0
- Reddit posts catalogued: 0
- X posts catalogued: 0
- Other anecdote sources (YouTube, Instagram, etc.): 0
- Total sources in chain: 4
Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.
Quantified confidence (this ledger): 0.5 / 1.00 — low–moderate — mostly preclinical
Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.
What scientists say
Clinical study of cerebrospinal fluid neuropeptides in patients with primary trigeminal neuralgia (source s1)
Human study measuring elevated VIP in TN patients' CSF and blood.
Evidence type: Tagged human evidence in this ledger — check sample size and design.
Observation of vasoactive intestinal polypeptide in patients with trigeminal neuralgia (source s2)
Human observation of VIP changes during TN attacks.
Evidence type: Tagged human evidence in this ledger — check sample size and design.
Distinct VIP and PACAP Functions in the Distal Nerve Stump Following Peripheral Nerve Injury (source s3)
Mouse study on VIP after nerve injury and anti-inflammatory effects.
Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.
Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Attacks (source s4)
Human trial showing VIP can induce migraine and vasodilation.
Evidence type: Tagged human evidence in this ledger — check sample size and design.
---
Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.
Evidence ledger 4 · tier-ranked · API
Ask this article · 6 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.